288 related articles for article (PubMed ID: 35203309)
1. The Mysterious Actor-γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL).
Zarobkiewicz MK; Bojarska-Junak AA
Cells; 2022 Feb; 11(4):. PubMed ID: 35203309
[TBL] [Abstract][Full Text] [Related]
2. Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells.
Siegers GM; Dhamko H; Wang XH; Mathieson AM; Kosaka Y; Felizardo TC; Medin JA; Tohda S; Schueler J; Fisch P; Keating A
Cytotherapy; 2011 Jul; 13(6):753-64. PubMed ID: 21314241
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD226 on γδ T cells is lower in advanced chronic lymphocytic leukemia and correlates with IgA, IgG and LDH levels.
Zarobkiewicz MK; Lehman N; Kowalska W; Dąbrowska I; Bojarska-Junak A
Adv Clin Exp Med; 2024 May; ():. PubMed ID: 38819939
[TBL] [Abstract][Full Text] [Related]
4. Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept.
Almeida AR; Correia DV; Fernandes-Platzgummer A; da Silva CL; da Silva MG; Anjos DR; Silva-Santos B
Clin Cancer Res; 2016 Dec; 22(23):5795-5804. PubMed ID: 27307596
[TBL] [Abstract][Full Text] [Related]
5. Quantification and phenotypic characterization of peripheral blood Vδ1 + T cells in chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
Simões C; Silva I; Carvalho A; Silva S; Santos S; Marques G; Ribeiro A; Roque A; Carda J; Sarmento-Ribeiro AB; Domingues MDR; Ribeiro L; Paiva A
Cytometry B Clin Cytom; 2019 Mar; 96(2):164-168. PubMed ID: 30334339
[TBL] [Abstract][Full Text] [Related]
6. Molecular diversity of gammadelta T cells in peripheral blood from patients with B-cell chronic lymphocytic leukaemia.
Bartkowiak J; Kulczyck-Wojdala D; Blonski JZ; Robak T
Neoplasma; 2002; 49(2):86-90. PubMed ID: 12088111
[TBL] [Abstract][Full Text] [Related]
7. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
Giordano Attianese GM; Marin V; Hoyos V; Savoldo B; Pizzitola I; Tettamanti S; Agostoni V; Parma M; Ponzoni M; Bertilaccio MT; Ghia P; Biondi A; Dotti G; Biagi E
Blood; 2011 May; 117(18):4736-45. PubMed ID: 21406718
[TBL] [Abstract][Full Text] [Related]
9. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia.
Scrivener S; Goddard RV; Kaminski ER; Prentice AG
Leuk Lymphoma; 2003 Mar; 44(3):383-9. PubMed ID: 12688308
[TBL] [Abstract][Full Text] [Related]
10. [Expression of CD5 antigen in B and T cells from umbilical cord blood, from blood of healthy adults and patients with chronic lymphocytic B-cell leukemia (PBL-B)].
Roliński J; Rupniewska ZM; Wasik-Szczepanek E
Pol Arch Med Wewn; 1999 Apr; 101(4):307-14. PubMed ID: 10740408
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukaemia: from genetics to treatment.
Bosch F; Dalla-Favera R
Nat Rev Clin Oncol; 2019 Nov; 16(11):684-701. PubMed ID: 31278397
[TBL] [Abstract][Full Text] [Related]
12. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
13. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.
Poggi A; Venturino C; Catellani S; Clavio M; Miglino M; Gobbi M; Steinle A; Ghia P; Stella S; Caligaris-Cappio F; Zocchi MR
Cancer Res; 2004 Dec; 64(24):9172-9. PubMed ID: 15604289
[TBL] [Abstract][Full Text] [Related]
14. Modulation and high frequency expression of autoantibody-associated cross-reactive idiotypes linked to the VHI subgroup in CD5-expressing B lymphocytes from patients with chronic lymphocytic leukaemia (B-CLL).
Shokri F; Mageed RA; Richardson P; Jefferis R
Scand J Immunol; 1993 Jun; 37(6):673-9. PubMed ID: 7686301
[TBL] [Abstract][Full Text] [Related]
15. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
16. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.
Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895
[TBL] [Abstract][Full Text] [Related]
17. TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia.
Szymańska A; Bojarska-Junak A; Drobiecki A; Tomczak W; Roliński J; Hus M; Hus I
Arch Immunol Ther Exp (Warsz); 2019 Feb; 67(1):55-65. PubMed ID: 30196472
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling.
Friedman DR; Guadalupe E; Volkheimer A; Moore JO; Weinberg JB
Br J Haematol; 2018 Dec; 183(5):747-754. PubMed ID: 30407619
[TBL] [Abstract][Full Text] [Related]
19. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
Lorentzen CL; Straten PT
Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
[TBL] [Abstract][Full Text] [Related]
20. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
